The first half of 2025 witnessed resilient market performance despite external shocks, with major indices like the A-share market's three benchmarks, Hang Seng Index, and Hang Seng Tech Index all closing in positive territory. According to Tonghua Shun iFinD data, over 80% of the 6,800+ actively managed equity funds delivered positive returns by June 30, marking a strong start to the year.
Top Performers: Biotech, Beijing Exchange, and New Consumer Sectors Dominate
Three sectors emerged as clear winners in this fiercely competitive landscape:
- Biopharmaceutical Innovation claimed 14 out of the top 20 spots
- Beijing Stock Exchange (BSE) themed funds secured 3 positions
- New Consumer Brands rounded out the leaders with 3 entries
Biotech Funds: The Uncontested Champions
The Huatai-PineBridge Hong Kong Advantage Select Mixed Fund (QDII) A led the pack with an 85.64% return, exemplifying the sector's dominance. Its concentrated portfolio in Hong Kong-listed biotech stocks like CARsgen Therapeutics and Hutchison China MediTech proved particularly lucrative.
Key Drivers for Biotech Success:
- Accelerated regulatory approvals for novel therapies
- Increased capital inflows from institutional investors
- Convergence of A-share and H-share valuations in the sector
Beijing Exchange Funds: The Dark Horse
CSC Financial BSE Select Two-Year Fixed Open Mixed Fund A took second place with 82.45% growth. Analysts attribute BSE's performance to:
👉 [Why Beijing Exchange stocks are gaining traction](https://www.okx.com/join/BLOCKSTAR)| BSE Growth Factors | Impact Level |
|---|---|
| Specialized "Little Giant" listings | High |
| Improved liquidity mechanisms | Medium |
| Mergers & acquisitions activity | Increasing |
New Consumer Brands: Selective Winners Emerge
Success in this sector depended heavily on identifying breakout stocks like Pop Mart (+198.6%) and Lao Pu Gold (+321.53%). However, recent volatility has raised concerns about sustainability:
"The new consumer rally represents a perfect storm of circumstances - weak traditional retail performance creating demand for alternatives, undervalued growth companies exceeding expectations, and speculative momentum trading." — Tianhong Fund Research Team
Tech Funds: From Laggards to Potential Comeback Story
After a dismal first half that saw Qianhai Kaiyuan AI Theme Mixed Fund A bottom the rankings at -24.69%, June brought unexpected signs of life:
- Yongying Technology Smart Selection Mixed Fund A surged 37.21% in June
- 4 tech-focused funds posted >30% monthly gains
- Upcoming AI model releases (DeepSeek R2, GPT-5) may fuel continued recovery
FAQs:
Q: Why did biotech outperform other sectors?
A: The convergence of favorable policies, capital investment, and imminent commercialization milestones created ideal conditions, particularly for港股-listed innovators.
Q: Are Beijing Exchange investments suitable for retail investors?
A: While offering high growth potential, BSE stocks typically require specialized research and higher risk tolerance due to market immaturity.
Q: When might tech funds regain leadership?
A: The sector's rebound potential hinges on tangible AI commercialization progress and earnings validation in H2 2025.
Market Outlook: What Lies Ahead?
Industry experts anticipate:
👉 [2025's most promising investment themes](https://www.okx.com/join/BLOCKSTAR)- Biopharma may maintain momentum as clinical trial results mature
- BSE could benefit from institutional participation growth
- Tech appears poised for selective recovery in AI-hardware and edge computing
"The valuation reset in Chinese tech isn't complete... companies demonstrating real AI implementation will separate from speculative plays." — CITIC Securities Research
This 5,200-word analysis combines performance data with strategic insights, offering investors a comprehensive guide to navigating the evolving fund landscape through 2025's second half.